GILD
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F2836596&ei=kXKaUvDOH7Hr0QGFIA&usg=AFQjCNGvw5V7ioStm_WLrxLQaFwqpvFPFw
European Commission Approves Gilead Sciences Inc's New Boosting Agent For HIV Therapy
Wednesday, 25 Sep 2013 04:30pm EDT
Gilead Sciences Inc announced that the European Commission has granted marketing authorization for once daily Tybost (cobicistat 150 mg tablets), a pharmacokinetic enhancer that boosts blood levels of certain HIV medicines. Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir 300 mg once daily and darunavir 800 mg once daily as part of antiretroviral combination therapy in adults with HIV-1 infection. The approval allows for the marketing of Tybost in all 28 countries of the European Union (EU).Â 
